IGI Logo

Zydus Lifesciences is currently trading at Rs. 930.90, up by 8.80 points or 0.95% from its previous closing of Rs. 922.10 on the BSE.

The scrip opened at Rs. 934.55 and has touched a high and low of Rs. 934.55 and Rs. 922.85 respectively. So far 7505 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 937.00 on 23-Feb-2024 and a 52 week low of Rs. 452.20 on 27-Feb-2023.

Last one week high and low of the scrip stood at Rs. 937.00 and Rs. 888.55 respectively. The current market cap of the company is Rs. 93694.68 crore.

The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.03% and 6.99% respectively.

Zydus Lifesciences has received the WHO prequalification approval for the API and formulation of the key drug to treat Leishmaniasis, ‘Miltefosine’. With this, Miltefosine will be added to WHO’s pre-qualification list which will enable larger access to the drug globally.

Leishmaniasis is caused by protozoan parasites which are transmitted by the bite of infected female phlebotomine sandflies. The disease affects some of the world’s poorest people and is associated with malnutrition, population displacement, poor housing, a weak immune system and lack of financial resources.

According to WHO, there are three main forms of the disease: cutaneous leishmaniasis (CL), visceral leishmaniasis (VL), also known as kala-azar, and mucocutaneous leishmaniasis (MCL). CL is the most common form, VL is the most severe form and MCL is the most disabling form of the disease. VL if left untreated, causes death in more than 90% of cases. An estimated 700 000 to 1 million new cases and an estimated 30 000 new cases of VL occur annually. In 2018, 92 and 83 countries or territories were considered endemic for, or had previously reported cases of, CL and VL, respectively. 

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.